ArticleEuropean journal of medical research2026
Therapeutic potential of CDK8 inhibitor combined with sorafenib for hepatocellular carcinoma: mechanistic insights and in vitro validation.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAlthough the prognosis of hepatocellular carcinoma (HCC) has been improved significantly due to diagnostic innovation and treatment optimization, HCC remains highly lethal, necessitating novel therapeutic targets. MATERIALS AND
methodsCDK8 expression was assessed in 75 HCC and paracancerous tissues by immunohistochemistry. Integrated analysis of 3969 HCC and 3245 non-tumor liver samples from RNA-seq and microarray datasets was performed. CDK8's functional mechanisms were explored through genetic alteration, immune infiltration, co-expression networks, and single-cell RNA-seq analyses. In vitro experiments including cell proliferation assay, scratch assay and transwell assay were conducted for investigating the effect of combined use of CDK8 inhibitor MSC2530818 and sorafenib on the biological functions of Huh7 cells.
resultsCDK8 was significantly overexpressed in HCC tissues, correlating with immune cell infiltration and advanced clinical stage. Single-cell analysis revealed prominent CDK8 expression in T/NK cells, myeloid cells, and cancer cells from advanced HCC samples. The carcinogenic role of CDK8 in HCC might be explained by the enrichment of co-expressed genes in biological processes including mRNA metabolic process, cell division and DNA conformation change. Combination of CDK8 inhibitor and sorafenib exerted more potent inhibition on cell growth, migration and invasion of Huh7 cells than monotherapy.
conclusionCDK8 is highly expressed in HCC tissues, suggesting its oncogenic role. Our in vitro findings demonstrate that the CDK8 inhibitor MSC2530818 synergizes with sorafenib to enhance anti-tumor efficacy against HCC cells, supporting further investigation of this combination strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.